A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners  by Crouin, Catherine et al.
A yeast two-hybrid study of human p97/Gab2 interactions with its SH2
domain-containing binding partners
Catherine Crouina, Mary Arnauda, Franck Gesberta;1, Jacques Camonisb, Jacques Bertoglioa;*
aInserm Unit 461, Faculte¤ de Pharmacie Paris-XI, 5 rue Jean-Baptiste Cle¤ment, 92296 Cha“tenay-Malabry, France
bInserm Unit 528, Institut Curie, 26 rue d’Ulm, 75248 Paris, France
Received 21 March 2001; accepted 27 March 2001
First published online 10 April 2001
Edited by Giulio Superti-Furga
Abstract p97/Gab2 is a recently characterized member of a
large family of scaffold proteins that play essential roles in signal
transduction. Gab2 becomes tyrosine-phosphorylated in response
to a variety of growth factors and forms multimolecular
complexes with SH2 domain-containing signaling molecules such
as the p85-regulatory subunit of the phosphoinositide-3-kinase
(p85-PI3K), the tyrosine phosphatase SHP-2 and the adapter
protein CrkL. To characterize the interactions between Gab2
and its SH2-containing binding partners, we designed a modified
yeast two-hybrid system in which the Lyn tyrosine kinase is
expressed in a regulated manner in yeast. Using this assay, we
demonstrated that p97/Gab2 specifically interacts with the SH2
domains of PI3K, SHP-2 and CrkL. Interaction with p85-PI3K
is mediated by tyrosine residues Y452, Y476 and Y584 of Gab2,
while interaction with SHP-2 depends exclusively on tyrosine
Y614. CrkL interaction is mediated by its SH2 domain
recognizing Y266 and Y293, despite the latter being in a non-
consensus (YTFK) environment. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
p97/Gab2 is a recently characterized member of the large
IRS/Gab family of sca¡old proteins that become tyrosine-
phosphorylated in response to a variety of growth factors,
and integrate multiple signaling pathways. Gab2 was initially
identi¢ed in hematopoietic cells, as a 97-kDa protein phos-
phorylated in response to various stimuli such as stimulation
by cytokines, cross-linking of T- or B-lymphocyte receptors or
transformation by Bcr/Abl [1^3]. We previously reported that
p97/Gab2 is a major tyrosine kinase substrate in interleukin-2-
stimulated human T-lymphocytes, and is associated in a stim-
ulation-dependent manner with phosphoinositide-3-kinase
(PI3K), with the tyrosine phosphatase SHP-2 and with the
adapter protein CrkL [4]. Pull down experiments using a panel
of GST fusion proteins allowed us to demonstrate that these
interactions are mediated by the Src homology 2 domain
(SH2) domains of these proteins recognizing tyrosine-phos-
phorylated Gab2. Subsequent to the cloning of murine and
human Gab2 [5^7], sequence analysis revealed the presence of
four putative recognition sequences (pYxxP, where pY stands
for phosphotyrosine) for the CrkL SH2 domain, three puta-
tive recognition sequences (pYxxM) for the p85 PI3K subunit
SH2 domains and two putative recognition sequences
(pYxxV/L) for the SH2 domains of SHP-2. Since yeasts do
not express endogenous tyrosine kinase, the conventional
yeast two-hybrid system cannot be used to study SH2/phos-
photyrosine interactions, unless one of the partners is itself a
tyrosine kinase. Indeed, such an approach has been used to
characterize the interactions of SHP-2 or IRS-1 with the in-
sulin receptor kinase and with the IGF-I receptor, that auto-
phosphorylate, and to study association of the Lyn tyrosine
kinase with Cbl [8^10].
In an attempt to further characterize the interactions be-
tween Gab2 and its SH2-containing binding partners, we de-
signed a modi¢ed yeast two-hybrid system in which the cata-
lytic domain of Lyn, a member of the Src family of tyrosine
kinases, is expressed in a regulated manner in yeast. Using this
assay, we demonstrated that indeed p97/Gab2 interacts with
the SH2 domains of p85-PI3K, SHP-2 and CrkL, but not with
those of Shc or of either STAT5 isoforms. Interaction with
p85-PI3K is mediated by tyrosine residues Y452, Y476 and Y584
as predicted by Gab2 sequence analysis, while interaction with
SHP-2 appears to depend exclusively on tyrosine Y614. With
regards to CrkL interaction, three of the four predicted sites
appear not to be functional, and the CrkL SH2 domain only
recognizes e⁄ciently Y266 and Y293, despite the latter being in
an unusual (YTFK) sequence environment for CrkL^SH2
recognition.
2. Materials and methods
2.1. Plasmid constructs
cDNAs for the human CrkL SH2 domain (aa 1^127), tandem SH2s
of human p85 K (aa 313^724) and of murine SHP-2 (aa 1^240) were
excised from previously described pGEX vectors [4] and inserted in
frame in appropriate derivatives of the pLexA vector. cDNA for
human p97/Gab2 was ampli¢ed by polymerase chain reaction
(PCR) from plasmid KIAA0571/AB011143 (a kind gift of Dr T. Na-
gase, Kazusa DNA Research Institute, Japan). Full length cDNA for
human Gab2 was obtained by PCR of reverse transcribed Kit 225 cell
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RNA, using a 5P primer oligonucleotide designed after the published
sequence [7]. Full length cDNA as well as Gab2 subdomains were
inserted in frame in a pGad vector whose multiple cloning site had
been modi¢ed by oligonucleotide insertion. In some instances, as de-
scribed below, the reverse constructs, i.e. Lex-Gab2 and Gad-p85 were
used.
Mutations of tyrosine residues in Gab2 were performed using the
Quikchange mutagenesis kit (Stratagene) according to the manufac-
turer’s instructions.
For expression of the Lyn kinase in yeast, the cDNA encoding the
tyrosine kinase domain of murine Lyn (aa 241^512) was ampli¢ed by
PCR from a full length cDNA kindly provided by Dr. J. Cambier
(Denver, CO, USA), tagged with the myc epitope and inserted in
pMET416 under control of the methionine-regulated Met25 promoter
[11].
All constructs, whether wild type or mutated, were veri¢ed by DNA
sequencing.
2.2. Two-hybrid experiments
All yeast transformations were performed by the lithium acetate
method. The TAT7 strain of Saccharomyces cerevisiae (MATa, his3
leu2 trp1 ade2 LYS2: :lex(op)-HIS3 ura3: :lex(op)-LacZ), a gift
from Dr R. Sternglanz (New York State University, NY, USA),
was transformed with either pLex or pGad constructs or both, and
transformants selected on appropriate selective medium (3Trp,
3Leu). For introducing the Lyn kinase, TAT7 yeasts were mated
with yeast strain W303-1A/D (MATalpha his3 leu2 trp1 ade2 ura3)
transformed with pMET416-Lyn or empty pMET416 that contains a
URA3 selection marker [12]. Following overnight mating on YPDA
medium, patches were replicated on plates lacking Ura, Trp and Leu
for selection of diploids. All interactions were tested in at least two
independent transformations.
2.3. Filter and liquid L-galactosidase assays
For ¢lter L-galactosidase assays, yeast patches were replica-lifted
onto Whatman 40 ¢lter paper and grown for 24 h. After freezing in
liquid nitrogen, ¢lters were laid over a Whatman 3 ¢lter soaked in Z
bu¡er (50 mM sodium phosphate bu¡er, pH 7.0, 10 mM KCl, 1 mM
MgSO4) with 0.5% L-mercaptoethanol (LME) and 0.2 mg/ml 5-bro-
mo-4-chloro-3-indolyl-L-D-galactopyranoside (X-gal) (Boehringer).
After 2^6 h the reaction was stopped by transferring the ¢lters to a
1 M Na2CO3 solution.
For liquid L-galactosidase assays, yeast was grown overnight on
appropriate selective media and OD600 were recorded. Cells were pel-
leted by centrifugation from 1 ml aliquots of each culture and per-
meabilized by ¢ve cycles of freeze-thawing in 100 Wl of Z bu¡er. Then,
700 Wl of Z bu¡er plus LME and 150 Wl of 2-nitrophenyl-L-D-galac-
topyranoside (ONPG, 4 mg/ml in H2O) were added. The reaction was
incubated at 30‡C until color developed and OD420 was recorded.
Results are expressed as Miller units: one unit of L-galactosidase
was de¢ned as (OD420U1000)/(OD600Uvolume (ml)Utime (min)).
2.4. Western blot analysis
For Western blot analysis, yeast was grown overnight and recov-
ered by centrifugation. Total yeast extracts were obtained by incuba-
tion in lysis bu¡er (Tris-bu¡ered saline pH 8, 1% Triton X), followed
by ¢ve cycles of freeze-thawing. Proteins (50 Wg) were separated by
SDS^PAGE and electro-transferred to nitrocellulose according to
standard methods. The 9E10 antibody (anti-myc) and 4G10 (anti-
phosphotyrosine) were used together with HRP-conjugated anti-
mouse antibodies and ECL reagent as described. Cell extracts from
starved or IL-2-stimulated Kit 225 cells were immunoprecipitated as
previously described [4] with a Gab2 speci¢c goat antiserum (sc-9313,
Santa Cruz Biotech, CA, USA) and analyzed by Western blotting
with indicated antibodies.
2.5. Peptide binding of CrkL
Biotinylated peptides designed after the sequence of human Gab2
were purchased from Sigma-Genosys. Peptides (5 Wg), phosphorylated
on tyrosine or not, were coupled overnight to streptavidin^agarose
beads. Beads were washed and incubated for 2 h with Kit 225 cell
lysates (800 Wg) or GST^CrkL^SH2 fusion protein (5 Wg). Beads were
washed, boiled in sample bu¡er and the eluted material analyzed by
Western blotting with anti-CrkL antiserum (sc-319, Santa Cruz Bio-
tech., CA) or anti-GST antibodies.
3. Results
3.1. Tyrosine phosphorylation-dependent interaction of Gab2
with the SH2 domains of CrkL, PI3K and SHP-2
At the time of our previous report describing the phosphor-
ylation of p97 in response to IL-2 stimulation in human T-
lymphocytes [4], Gab2 had not yet been identi¢ed, and no
speci¢c antibodies were therefore available. We ¢rst wanted
to con¢rm our previous ¢ndings using a Gab2 speci¢c anti-
serum, and the data shown in Fig. 1 indeed clearly evidenced
the tyrosine phosphorylation of Gab2 in IL-2-stimulated Kit
225 cells, and its interactions with p85-PI3K, SHP-2 and
CrkL. To further analyze the interactions of p97/Gab2 with
the SH2 domains of these proteins, we next established a
modi¢ed two-hybrid system in which expression of the Src
family kinase Lyn is repressed by the presence of methionine
in the growth medium [11]. This was achieved by cloning the
catalytic domain of Lyn under the control of the Met25 pro-
moter on a centromeric URA plasmid. As seen in Fig. 2,
when yeasts were grown in the absence of methionine, the
kinase was expressed, as detected with the anti-myc antibody,
and as a result a large number of yeast proteins became highly
phosphorylated on tyrosine residues. It is of interest that ex-
pression of the kinase showed no deleterious e¡ect on yeast
growth. In the presence of 200 mg/l methionine, very little
kinase was detectable (lanes 4 and 6, top panel) and tyrosine
phosphorylation of endogenous substrates was minimal.
Fig. 1. Phosphorylation of Gab2 and protein interactions in IL-2-
stimulated Kit 225 cells. Cell lysates from starved or IL-2-stimulated
Kit 225 cells, were immunoprecipitated with anti-Gab2 antibodies
and protein G Sepharose beads. Following SDS^PAGE separation,
the precipitated material was analyzed by Western blotting with the
indicated antibodies.
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This modi¢ed two-hybrid system was then used to analyze
the interactions of full length Gab2 with a variety of SH2
domains that are relevant to signaling by the interleukin 2
receptor in human lymphocytes [13]. As shown in Fig. 3, ex-
pression of the Lyn kinase did not a¡ect a positive control
interaction between Ras(V12) and Raf. Expression of the ki-
nase also yielded no background with any of the pLex-SH2
domains when tested against empty pGad. Interaction of
Gab2 was clearly detectable with the SH2 domains of CrkL
and of SHP-2 in the presence of active Lyn. For reasons that
have not yet been clari¢ed, a constitutive interaction occurred
between Gab2 and the SH2 domains of p85 PI3K, even in the
presence of empty pMET416. Quantitation in a liquid L-ga-
lactosidase assay of the interaction occurring when Lyn was
expressed however revealed a tyrosine phosphorylation-depen-
dent interaction above background (data not shown). Invers-
ing the constructs, i.e. cloning the p85-SH2s into pGad and
Gab2 into pLex eliminated the background and clearly dem-
onstrated that an interaction did take place between Gab2
and the p85 SH2s depending on Lyn expression (compare
lines 7 and 9 in Fig. 3). Therefore, all subsequent studies of
Gab2/p85 interactions were done in this orientation. However,
incomplete repression of the kinase probably accounts for the
interaction being still detectable in the presence of methionine.
All positive interactions described above have been con¢rmed
in a histidine prototrophy assay (not shown). Finally, Gab2
did not interact in this assay with the SH2 domains of Shc or
of either STAT5 isoforms (a and b) that are known to be
involved in interleukin-2 signaling [14^16].
3.2. Gab2 subdomains interacting with CrkL, SHP-2 and PI3K
SH2 domains bind to speci¢c target sequences, depending
on the nature of the residue located in position +3 relative to
the phosphorylated tyrosine, that de¢ne consensus binding
sites for a given SH2 [17]. Of practical interest, the putative
binding sites for CrkL, PI3K and SHP-2 are ordered in three
separate clusters on the Gab2 molecule. Indeed four consen-
sus recognition sequences (YxxP) for the Crk SH2 are located
at positions 249, 266, 324, and 409, three recognition sequen-
ces (YxxM) for p85 SH2s are located at positions 452, 476
and 584 and two recognition sequences (YxxV/L) for SHP-2
SH2s are located at positions 614 and 643. We therefore con-
structed, and analyzed for their interactions, Gab2 subdo-
mains comprising aa 233^432, 445^611 and 601^676. The re-
sults of these experiments (shown in Fig. 4A) clearly
evidenced the interactions with the three SH2 constructs and
con¢rmed that they were restricted to the predicted subregions
of Gab2. In addition, quantitation of these interactions in a
liquid L-galactosidase assay indicated that SHP-2 associated
with Gab2 in a somewhat weaker manner than PI3K or CrkL
did (Fig. 4B).
3.3. Identi¢cation of tyrosine residues involved in Gab2
interactions with PI3K, SHP-2 and CrkL SH2 domains
Having located the subregions of Gab2 that interact with
each of the partner SH2 domains, we undertook to systemati-
cally mutate into phenylalanine every tyrosine residue that is
Fig. 2. Regulated expression of catalytic Lyn in yeast. Yeast dip-
loids were obtained by mating W303 transformed with empty
pMET416 vector (EV) or pMET416-Lyn (Lyn) with TAT7 trans-
formed with empty pGad and either empty pLex (lanes 1,2), pLex-
p85 (lanes 3,4) or pLex-SHP-2 (lanes 5,6). Cells were grown over-
night in selective medium plus/minus methionine (MET) and protein
extracts analyzed by Western blotting with 9E10 anti-myc or 4G10
anti-phosphotyrosine antibodies.
Fig. 3. Tyrosine phosphorylation-dependent interaction of Gab2
with the SH2 domains of CrkL, PI3K and SHP-2. Yeast diploids
were obtained by mating W303 transformed with empty pMET416
vector (EV) or pMET416-Lyn (Lyn) with TAT7 transformed with
the indicated constructs. Yeasts were grown overnight on ¢lters lay-
ered over plates containing or not methionine. The ¢lter L-galactosi-
dase assays were performed as described in Section 2. The data
shown are pooled from three experiments, each performed at least
twice with identical results.
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potentially implicated in these interactions. This was per-
formed by sequential mutagenesis on the three subregion-en-
coding plasmids, and the overall data for ¢lter and liquid L-
galactosidase assays are shown in Table 1.
3.3.1. Tyrosine residues involved in p85-PI3K
recognition. The p85-SH2 interacting subregion of Gab2
(aa 445^611) contains three tyrosine residues at position
452, 476, 584 which are followed by a M in position +3.
Mutating into phenylalanine all three tyrosines completely
abrogated the interaction, and anyone of these tyrosine resi-
dues, when expressed alone, yielded signi¢cant L-galactosidase
activity. Thus all three tyrosines predicted to bind p85 are
indeed functional in this assay. Although di¡erences in the
level of L-galactosidase activity were reproducibly observed,
Fig. 4. Gab2 subdomains interacting with CrkL, SHP-2 and PI3K. A: schematic representation of Gab2 subregions, and ¢lter L-galactosidase
assay performed in the absence of methionine. B: Liquid L-galactosidase assay performed in the absence (¢lled bars) or in the presence (open
bars) of methionine. The following combinations were used: the SH2 domains of SHP-2 or CrkL were inserted in pLex and tested against
Gab2 inserted in pGad; the p85 SH2s were inserted in pGad and tested against pLex-Gab2.
Table 1
Identi¢cation of tyrosine residues involved in Gab2 interactions
P97 mutants Y residue(s) expressed ¢lter assay (3Met) Liquid assay (Miller units)a
(3 Met) (+Met)
PI3K interactionb
YYY all Blue 15.7 3.3
FFF none White 0.50.8
YFF 452 Blue 13.9 2.0
FYF 476 Blue 25.7 2.0
FFY 584 Blue 8.9 1.4
YYF 452, 476 Blue 24.3 2.5
FYY 476, 584 Blue 15.3 2.1
YFY 452, 584 Blue 23.7 2.3
SHP-2 interactionc
YY both Blue 2.2 0.1
FF none White 0.20.0
YF 614 Blue 3.2 0.1
FY 643 White 0.1 0.1
CrkL interactiond
YYYYYY all Blue 14.8 0.8
FFYFFY 293, 411 Blue 37.8 1.0
FFFFFF none White 0.6 0.5
YFFFFF 249 White 0.8 0.5
FYFFFF 266 Blue 64.4 1.0
FFYFFF 293 Blue 35.7 1.0
FFFYFF 324 White 0.7 0.5
FFFFYF 409 White 0.7 0.5
FFFFFY 411 White 0.7 0.5
YFFYYY 249, 324, 409, 411 White 0.7 0.5
aData shown are the mean of two independent determinations.
bAssayed with pLex-Gab2(445^611) versus pGad-p85-(N+C)SH2.
cAssayed with pGad-Gab2(601^676) versus pLex-SHP-2-(N+C)SH2.
dAssayed with pGad-Gab2(233^432) versus pLex^CrkL^SH2.
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we could not establish a clear hierarchy between individual
tyrosine residues (or pairs) regarding their relative importance
in the interaction.
3.3.2. Tyrosine residues involved in SHP-2 interaction. The
SH2 domains of SHP-2 have been described to preferentially
recognize pY followed either by V or by L in position +3 [17].
Thus the two tyrosine residues at the C-terminal end of Gab2
(Y614LAL and Y643VQV) represent potential binding sites for
SHP-2. The results shown in Table 1 however demonstrate
that Y614 alone mediates this interaction. Indeed, mutation
of Y643 had no detectable e¡ect on the interaction, yielding
almost identical values as the wild type in the assay, whereas
mutation of Y614 completely abrogated the interaction.
3.3.3. Tyrosine residues involved in CrkL SH2
recognition. Within the CrkL-binding subdomain, which
contains six Y residues, we initially mutated the four Y resi-
dues (at positions 249, 266, 324, and 409) that are followed by
P in position +3 and may thus represent putative binding sites
for CrkL SH2. Unexpectedly, a strong interaction was still
detected, as measured in the liquid assay for L-galactosidase
activity with this FFYFFY mutant (Table 1). Mutating to F
the remaining two Y (Y293TFK and Y411PQR) in this region
abolished the interaction. To identify which residues was
(were) involved, single Y were reintroduced within the context
of the remaining ¢ve being F. As evidenced in Table 1 only
residues Y266 and Y293, when expressed alone mediated sig-
ni¢cant binding. These two residues accounted for all the
interaction between CrkL and Gab2, since the YFFYYY mu-
tant was negative in this assay. Thus out of the four YxxP
sequences, only one (Y266DLP) appears to be involved in
binding CrkL SH2, together with Y293 whose environment
(YTFK) does not ¢t the consensus but which is also clearly
recognized by CrkL SH2.
3.4. In vitro binding of CrkL with Gab2-derived peptides
Since the interaction of CrkL with Y293 was not predicted
based on known consensus, we sought to con¢rm it by a
biochemical approach. 15-amino acid long peptides centered
on Y266 and on Y293 were synthesized, with the tyrosine phos-
phorylated or not, and used to study association of either
natural CrkL, as provided in Kit 225 cell lysates, or recombi-
nant CrkL SH2 domain produced as a GST fusion protein.
As seen in Fig. 5, both the GST^CrkL^SH2 and the endog-
enous CrkL associated e⁄ciently with the Y293 phosphopep-
tide and with the Y266 phosphopeptide. This interaction was
indeed found to depend upon peptide 293 being tyrosine-
phosphorylated, and its speci¢city further con¢rmed in that
none of the peptides used in these experiments interacted with
SHP-2 (data not shown).
4. Discussion
Interactions of SH2 domains with phosphorylated tyrosines
are critical for signal transduction from many membrane re-
ceptors [18,19]. In recent years it has been found that adapter
proteins of the IRS/Gab family bind multiple SH2 domain-
containing molecules and provide both time and space coor-
dination to multiple signaling pathways. Gab2 contains 19
tyrosine residues, and although the identi¢cation of which
residues are actually phosphorylated in growth factor-stimu-
lated cells has not been reported, 11 of these residues are
preceded by acidic (E or D) amino acids and are thus poten-
tial phosphorylation sites for Src family kinases [20]. The var-
ious stimuli that lead to Gab2 phosphorylation have all in
common that they activate members of the Src family. In
preliminary experiments we found that the p56lck tyrosine
kinase did not perform well in this yeast two-hybrid system.
We therefore decided to use Lyn, another Src kinase involved
in signaling in lymphoid cells, in our modi¢cation of the two-
hybrid system to identify tyrosine residues which are critical
for the association of human Gab2 with p85-PI3K, SHP2 and
CrkL. Our use of a methionine regulatable promoter to ex-
press the catalytic domain of Lyn provided internal control,
formally establishing that the interactions we describe here
depend on phosphorylation. We ¢rst identi¢ed three subre-
gions of Gab2 that interact with p85, SHP2 and CrkL, where-
as the PH domain-containing N-terminal region (aa 1^276)
did not associate with any of the SH2 domains studied here
(not shown).
Shc is an essential adapter that recruits Gab2 to phosphor-
ylated receptors. In most cases, Shc recognizes phosphorylat-
ed receptors through its PTB domain, and is then phosphor-
ylated, thus providing a docking site for Grb2 to which Gab2
is bound through SH3/polyproline interactions [16,21,22].
Although it has previously been suggested that Shc could
associate with Gab2, depending on its SH2 domain [23], our
experiments did not evidence such an interaction, indicating
that it is most likely indirect, or of too low an a⁄nity to be
detected in this yeast two-hybrid assay. Other SH2 domains
that we found not to interact with Gab2 in this assay are
those of STAT5, which are not co-immunoprecipitated with
Gab2 in interleukin-2 stimulated lymphocytes (not shown).
Association of Gab2 with p85-PI3K was straightforward as
the three Y residues which, based on sequence environment,
are predicted to associate with p85-PI3K SH2 were found to
yield strong interactions in this assay. In contrast, although
two Y residues of Gab2 (i.e. Y614 and Y643) were predicted to
mediate interaction with SHP2 SH2, mutating Y614 alone
completely abrogated the interaction. A similar observation
has been made for Gab1, which, of the two homologous Y
Fig. 5. In vitro interactions of CrkL with Gab2-derived phospho-
peptides. Biotinylated synthetic phosphopeptides centered on human
Gab2 Y266 (266pY, sequence: EFRDST[pY]DLPRSLAS) and on
Y293 (293pY, sequence: TDNEDV[pY]TFKTPSNT) were coupled
to streptavidin beads and incubated with either Kit 225 cell lysates
(A) or puri¢ed GST^CrkL^SH2 fusion protein (B). Uncoupled
beads and non-phosphorylated Y293 peptide (293) were used as
controls. Western blots were performed with a CrkL antiserum (A)
or with anti-GST antibodies (B).
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residues (627 and 659) appears to only use the former to
associate with SHP-2 [9]. However, it cannot be totally ex-
cluded that Y643 could be recognized with too low an a⁄nity
to give a detectable interaction in the yeast two-hybrid. In-
deed, a model has been proposed whereby the SHP2 N-ter-
minal SH2 domain binds phosphotyrosine with a lower a⁄n-
ity than the C-terminal SH2 [24]. Thus, binding of the tandem
SH2 to a bisphosphoryl ligand would occur sequentially, with
initial high energy binding on one site by the C-SH2 allowing
the N-SH2 to then engage the second site. Our results suggest
that Gab2 Y614 might be a preferential binding site for the C-
SH2, and experiments aimed at verifying this hypothesis are
currently in progress. Others have already reported that mu-
tating the three YxxM in the PI3K-binding region of murine
Gab2 abrogates its binding to PI3K, and that mutating the
two C-terminal tyrosine residues abrogated binding to SHP-2,
and demonstrated that these interactions are critical for
downstream signaling events in cytokine response [25,26].
In contrast, the functional signi¢cance of the interaction
between Gab2 and CrkL has not yet been investigated.
CrkL is an adapter protein whose main partners are on one
hand the ras exchange factors C3G and SOS and, on the other
hand, the cytoskeleton regulatory proteins p125Fak and pax-
ilin [27^29]. Through these multiple interactions, CrkL may
thus be involved in the regulation of the ras pathway and
control cytoskeletal functions in response to growth factors
but also upon integrin activation [30]. In addition, CrkL itself
becomes tyrosine-phosphorylated in response to growth factor
stimulation [31]. CrkL contains two SH3 and one SH2 do-
mains. Whether the constitutive interaction between Gab2
and CrkL that is observed in unstimulated cells (Fig. 1) is
mediated by the CrkL SH3 domains recognizing Gab2 poly-
proline motifs has not been investigated in this study which
was focused on SH2^phosphotyrosine interactions. We dem-
onstrate here that the CrkL SH2 domain can indeed associate
with Gab2 in the yeast assay, and can recognize Gab2-derived
phosphopeptides. An unexpected ¢nding in this report is that
out of the four YxxP sequences which are present in the
CrkL-binding region of Gab2, only tyrosine Y266 mediates
signi¢cant interaction. Of note, Gab2 contains an additional
Y563CRP, within the PI3K-binding region, that does not ap-
pear to be recognized by CrkL. In contrast, CrkL SH2 does
interact with Y293TFK whose sequence environment does not
¢t the consensus. It may be of interest that Gab1 does not
contain an equivalent YTFK sequence, and that all of its
interaction with CrkL appears to depend upon typical YxxP
motifs [29].
Our results identifying the binding sites for these critical
partners of Gab2, provide the basis for introducing mutations
in Gab2 to speci¢cally abrogate these interactions and further
analyze their functional signi¢cance in cells. Finally, the mod-
i¢cation of the two-hybrid system described above could be
used to screen cDNA libraries for identifying new targets for
speci¢c SH2 domains.
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